Status Suspended
Process STA pre-2018
ID number 389
Referral date 01 December 2007
Topic area
  • Cancer
  • Digestive system

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC
2nd appraisal committee meeting TBC

Project Team

Assessment Group / Evidence Review Group: TBC
Communications manager: Alice Law
Executive Lead: Andrew Dillon
Project manager: TBC
Technical Lead: Andres Roman


Key events during the development of the guidance:

Date Update
26 June 2009

The manufacturer of capecitabine has advised us that they have not applied for regulatory approval in relation to this product at this time. The Institute has therefore decided to remove this appraisal from its current work programme.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance